Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance.
Radsak
M P
MP
Salih
H R
HR
Sökler
M
M
Kanz
L
L
Denzlinger
C
C
D000208:Acute Disease; D000368:Aged; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012074:Remission Induction
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000922:Immunotoxins; D007376:Interleukin-2; D000079982:Gemtuzumab